Innospark Ventures
VC Fund
Boston, United States
Innospark Ventures is a new breed of early-stage venture capital firm, investing in the AI-driven economy.
- Total investments:
- 58
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $100M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Innospark Ventures invests in
Stages Innospark Ventures invests in
Countries Innospark Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Seed
- $2.3M–$8.4M
- Pre-Seed
- $500k–$1.5M
- Series A
- $3.4M–$12M
Investment Focus
Industry
- Artificial Intelligence 17 (29%)
- Software 16 (28%)
- Health Care 13 (22%)
- Information Technology 11 (19%)
- Biotechnology 10 (17%)
Stage
- Seed 26 (45%)
- Series A 11 (19%)
- Pre-Seed 6 (10%)
- Funding Round 4 (7%)
- Series B 3 (5%)
Country
- United States 29 (50%)
- Canada 7 (12%)
- India 6 (10%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Matt Fates
Partner - AI VC
|
Partner - AI VC | Total investments: 22 | Find email | |
Mark Legare
Venture Investor
|
Venture Investor | Total investments: 1 | Find email | |
Venkat Srinivasan
Managing Director
|
Managing Director | Total investments: 11 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Antiverse
|
Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $9.3M / Series A / Mar 03, 2026 | |
Fourier Health
|
Fourier Health offers a platform that brings together clinical records from multiple sources and formats—such as PDFs, faxes, EHR data and handwritten notes—and transforms them into standardized, clinically meaningful summaries. The service supports a clinician-in-the-loop workflow so that outputs are verified and traceable back to originalsources, helping reduce data “hallucinations”. The system is configurable by specialty and use-case, enabling tailored summaries for providers in oncology, geriatrics or other areas, and it integrates with existing EHRs or document systems via APIs or Smart on FHIR apps. Fourier Health’s tools serve functions such as referral management, pre-visit readiness assessments, document labeling and triage, delivering actionable information directly into clinical workflows. | $8.4M / Seed / Oct 17, 2025 | |
Juniper Genomics
|
Juniper Genomics brings modern genomics and data science to those trying to conceive to help overcome barriers and challenges facing IVF patients. | $4.6M / Seed / Jun 26, 2025 | |
ArrePath
|
ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections. | Seed / Jun 23, 2025 | |
Persist AI
|
Persist assist pharmaceutical companies in developing long-acting formulations 50% faster. Because the formulation development process is manual and relies on scientific intuition, it takes a pharmaceutical company 5-10 years to develop a long acting formulation for a drug. This effort is divided into five years of pre-clinical development and fiveyears of clinical testing. Their goal is to use machine learning and automation to reduce the time required for pre-clinical formulation development to three months, making the formulation development process 50% faster. | $12M / Series A / Mar 19, 2025 | |
Copernic Catalysts
|
Copernic Catalysts develops sustainable chemical catalysts and processes. | $8M / Seed / Nov 12, 2024 | |
Phaseshift Technologies
|
PhaseShift Technologies is addressing the critical need for new materials that can overcome limitations in performance, efficiency, cost, availability, and sustainability. Traditional material development relies heavily on trial-and-error, requiring costly and time-consuming physical experiments. This approach can extend projects over 10-20 yearsand cost millions of dollars, with no guarantee of success.PhaseShift's Rapid Alloy Design (RAD)™ technology revolutionizes this process by using AI to create optimized alloys tailored to specific use cases. Paired with Multi-Scale Simulations to accurately predict material performance, RAD™ minimizes the time and effort spent on unsuccessful trials. This leads to faster, more efficient development cycles and a significant reduction in resources required to meet design goals.Through the RAD™ platform, PhaseShift designs a portfolio of innovative alloys, which are commercialized via strategic partnerships with manufacturers. | $3M / Seed / Oct 21, 2024 | |
|
Antiverse
|
Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $4.6M / Seed / Oct 15, 2024 | |
Haloo
|
Navigating the trademark search and registration process can be daunting and onerous for business owners and entrepreneurs. Heirlume is the first self-serve online trademark search and registration platform that integrates sophisticated legal thinking with technology. We make the complex trademark search and registration process fast, accurate,trusted and affordable for entrepreneurs and enterprise/e-com partners. Our search tool instantly runs the country-specific legal tests (i.e., “likelihood of confusion”) and performs lawyer analysis. Intelligent search algorithms provide an at-a-glance opinion of registerability (conflicts, descriptiveness, obscenity), displayed in simple visuals. Distilling the multiple data sets involved with drafting a trademark application requires time-consuming legal analysis. Our machine learning auto-suggest trademark application builder performs the lawyer work and removes room for error. While our first go to market strategy will target SME individual users, we see huge potential in expanding our market reach through key B2B partnerships as an upsell/add-on to a domain purchase (GoDaddy), or store set-up (Shopify or Amazon). Ultimately, we believe we can make trademark registration quick, easy and affordable, similar to the experience of registering a domain. | $3.4M / Series A / Jun 28, 2024 | |
Marigold Health
|
Marigold Health uses AI-augmented chat support groups to reach and retain patients with behavioral health needs in community-based treatment. Patients receive a personalized wraparound support while care teams see dramatic gains in capacity using patients to engage each other. We partner directly with treatment providers and managed careorganizations in the Medicaid market. | $11M / Series A / Jun 18, 2024 | |
| See all 58 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Innospark Ventures invest in?
Innospark Ventures invests primarily in Artificial Intelligence, Software and Health Care startups, most often at Seed and Series A stage. Most of the 58 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Innospark Ventures's check size?
Innospark Ventures typically joins rounds of $2.3M–$8.4M at Seed, $500k–$1.5M at Pre-Seed and $3.4M–$12M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Innospark Ventures participates in.
How do I contact Innospark Ventures?
Public channels for Innospark Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Innospark Ventures?
The team at Innospark Ventures includes Matt Fates (Partner - AI VC), Mark Legare (Venture Investor) and Venkat Srinivasan (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
